The Stoyanova lab develops new cancer early detection approaches and therapeutic strategies for late stage cancers. Current research areas of interest include targeted cancer therapies, antibody-based therapies, combination therapies for metastatic cancers, protein-based biomarkers for cancer early detection, and imaging modalities for cancer for prostate, breast, lung and other epithelial cancers. The ultimate goals of the laboratory are to improve the early diagnosis and prognosis of clinically significant cancers and guide the development of novel and effective therapeutic strategies for metastatic cancers.
Rice MA1, Kumar V1, Tailor D1, Garcia-Marques FJ, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Pandrala M, Nolley R, Ghoochani A, Liu S, Aslan M, Agarwal A, Buckup M, Hsu EC, Going CC, Peehl DP, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV#, Stoyanova T#. (2022). SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports Medicine. 3(2):100502. PMID: 35243415. 1equality contributed
Aslan M, Hsu EC, Garcia-Marques F, Bermudez A, Liu S, Shen M, Rice M, West R, Pitteri SJ, Balázs G, Stoyanova T#. (2021). Oncogene-mediated metabolic gene signature predicts breast cancer outcome. npj Breast Cancer. 7(1):141. PMID: 34711841
Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Ramasamy Paulmurugan R#, Stoyanova T#. (2021). Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Research. 81(6):1583-1594. PMID: 33483372
Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ#, Stoyanova T#. (2021). Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. British Journal of Cancer. 124(5):896-900. PMID: 33288843
Hsu E, Rice MA, Bermudez A, Fernando Marques F, Aslan M, Ghoochani A, Zhang A, Chen Y, Zlitni A, Habte F, Kumar S, Nolley R, Peehl DM, Zoubeidi A, Gambhir SS, Kunder C, Pitteri SJ, Brooks JD, Stoyanova T#. (2020). Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci USA (PNAS). 117(4):2032-2042. PMID: 31932422